AU2001293553A1 - Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment - Google Patents
Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatmentInfo
- Publication number
- AU2001293553A1 AU2001293553A1 AU2001293553A AU9355301A AU2001293553A1 AU 2001293553 A1 AU2001293553 A1 AU 2001293553A1 AU 2001293553 A AU2001293553 A AU 2001293553A AU 9355301 A AU9355301 A AU 9355301A AU 2001293553 A1 AU2001293553 A1 AU 2001293553A1
- Authority
- AU
- Australia
- Prior art keywords
- phosphatidylserine
- mimicking
- apoptosis
- bodies
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002319928A CA2319928A1 (en) | 2000-09-18 | 2000-09-18 | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| CA2319928 | 2000-09-18 | ||
| PCT/CA2001/001328 WO2002024162A1 (en) | 2000-09-18 | 2001-09-18 | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001293553A1 true AU2001293553A1 (en) | 2002-04-02 |
Family
ID=4167153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001293553A Abandoned AU2001293553A1 (en) | 2000-09-18 | 2001-09-18 | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6953591B2 (en) |
| EP (1) | EP1324750A1 (en) |
| JP (1) | JP2004508423A (en) |
| AU (1) | AU2001293553A1 (en) |
| CA (2) | CA2319928A1 (en) |
| WO (1) | WO2002024162A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI281407B (en) * | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| US20040265927A1 (en) * | 2001-09-18 | 2004-12-30 | Bolton Anthony E. | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| WO2003024422A1 (en) * | 2001-09-18 | 2003-03-27 | Vasogen Ireland Limited | Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| GB0207653D0 (en) * | 2002-04-03 | 2002-05-15 | Lamellar Therapeutics Ltd | Methods of using lamellar bodies for therapeutic purposes |
| WO2005007240A1 (en) * | 2003-07-21 | 2005-01-27 | Vasogen Ireland Limited | Combination treatment of neurological disorders comprising phospholipids |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| JP4891522B2 (en) * | 2003-10-03 | 2012-03-07 | 株式会社ファンケル | Serum GOT, GPT improving agent |
| JP2007522259A (en) * | 2004-10-20 | 2007-08-09 | ドゥサン コーポレーション | A composition containing phosphatidylserine for skin maintenance / improvement or skin barrier function enhancement |
| GB0426481D0 (en) * | 2004-12-02 | 2005-01-05 | Vaccine Technology Ltd | Composition |
| WO2006107107A1 (en) * | 2005-04-01 | 2006-10-12 | Fumitaka Ohsuzu | Myocardial protective agent comprising phospholipid liposome and method for prevention of myocardial disorder occurring under ischemia/reperfusion |
| WO2007041279A2 (en) * | 2005-09-29 | 2007-04-12 | S-Cell Biosciences, Inc. | Methods to treat t-cell disorders using tisf |
| ITRM20070394A1 (en) * | 2007-07-16 | 2009-01-17 | Uni Cattolica Del Sacro Cuo Re | ASYMMETRIC LIPOSOMAS AND THEIR USE IN MEDICAL FIELD. |
| EP2282723A2 (en) * | 2008-03-26 | 2011-02-16 | University of Oxford | Endoplasmic reticulum targeting liposomes |
| CN102427804A (en) | 2009-03-27 | 2012-04-25 | 牛津大学之校长及学者 | Cholesterol level lowering liposomes |
| WO2011098407A1 (en) * | 2010-02-12 | 2011-08-18 | Cemm Forschungszentrum Für Molekulare Medizin Gmbh | Microspheres |
| US10016371B2 (en) * | 2010-10-22 | 2018-07-10 | University Of Florida Research Foundation | Antigen-specific, tolerance-inducing microparticles and uses thereof |
| WO2012149393A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
| AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
| EP2877211A4 (en) * | 2012-07-25 | 2016-02-10 | Salk Inst For Biological Studi | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| EA201592103A3 (en) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | METHODS AND COMPOSITIONS FOR STRENGTHENING CD4 + REGULATORY T-CELLS |
| AU2014274894A1 (en) | 2013-06-04 | 2015-11-26 | Selecta Biosciences, Inc. | Repeated administration of non-immunosupressive antigen specific immunotherapeutics |
| PL3094345T3 (en) * | 2014-01-17 | 2018-11-30 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | Liposome-based immunotherapy |
| US20150374815A1 (en) | 2014-06-25 | 2015-12-31 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| GB201511058D0 (en) * | 2015-06-23 | 2015-08-05 | Lamellar Biomedical Ltd | Compositions and methods for using lamellar bodies for therapeutic purposes |
| WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| JP7262100B2 (en) | 2016-04-29 | 2023-04-21 | アイカーン スクール オブ メディスン アット マウント サイナイ | Targeting the innate immune system to induce long-term tolerance and resolve macrophage accumulation in atherosclerosis |
| US20180085319A1 (en) | 2016-09-27 | 2018-03-29 | Takashi Kei Kishimoto | Methods and compositions for treating cancer |
| AU2018205496A1 (en) | 2017-01-07 | 2019-07-25 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP3823980A1 (en) | 2018-07-16 | 2021-05-26 | Selecta Biosciences, Inc. | Methods and compositions of otc constructs and vectors |
| WO2020018587A1 (en) | 2018-07-16 | 2020-01-23 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
| CN114126666A (en) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | Methods for treating subjects with pre-existing immunity to viral transfer vectors |
| BR112021023594A2 (en) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Methods and compositions for attenuated antiviral transfer vector immune response |
| MX2023005224A (en) | 2020-11-04 | 2023-07-18 | Selecta Biosciences Inc | Compositions for reducing immune responses against immunoglobulin proteases. |
| CA3207247A1 (en) | 2021-01-05 | 2022-07-14 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| WO2022198101A1 (en) | 2021-03-19 | 2022-09-22 | Trained Therapeutix Discovery, Inc. | Compounds for regulating trained immunity, and their methods of use |
| EP4319747A1 (en) | 2021-04-09 | 2024-02-14 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| CA3235269A1 (en) | 2021-10-12 | 2023-04-20 | Cartesian Therapeutics, Inc. | Viral vector dosing protocols |
| WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| WO2024036324A1 (en) | 2022-08-11 | 2024-02-15 | Selecta Biosciences, Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1212900B (en) | 1983-11-17 | 1989-11-30 | Valle Francesco Della | THERAPEUTIC USE OF PHOSPHATIDYLSERINE IN DISEASES OF THE CENTRAL NERVOUS SYSTEM WITHOUT EFFECTS ON BLOOD COAGULATION |
| IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| US5231090A (en) | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| IT1247165B (en) | 1991-03-15 | 1994-12-12 | Fidia Spa | THERAPEUTIC USE OF PHOSPHATIDYLSERINE AND DERIVATIVES IN DEGENERATIVE PATHOLOGIES, ALSO ASSOCIATED WITH IMMUNITARY DYSFUNCTIONS. |
| DE4117629A1 (en) * | 1991-05-29 | 1992-12-03 | Max Planck Gesellschaft | Use of phosphatidyl serine derivs. - for treatment of depression and loss of cerebral function e.g. Parkinson's disease and Alzheimer's disease |
| US5292513A (en) * | 1992-05-18 | 1994-03-08 | Anthony G. Gristina | Method for nonspecific cellular immune stimulation |
| JP3714683B2 (en) | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | Anti-rheumatic agent |
| US6312719B1 (en) | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| WO1995023592A1 (en) * | 1994-03-04 | 1995-09-08 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US5948756A (en) | 1995-08-31 | 1999-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Therapeutic lipoprotein compositions |
| US6290987B1 (en) * | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| US6500810B2 (en) * | 1999-12-14 | 2002-12-31 | Sky High, Llc | Method of regulating expression of adhesion molecules on circulating leukocytes |
| EP1261785B1 (en) | 2000-03-07 | 2003-07-16 | E.F.P. Floor Products Fussböden GmbH | Panel, in particular flooring panel |
| WO2001066785A1 (en) * | 2000-03-08 | 2001-09-13 | National Jewish Medical And Research Center | Phosphatidyl serine receptors and uses thereof |
-
2000
- 2000-09-18 CA CA002319928A patent/CA2319928A1/en not_active Abandoned
-
2001
- 2001-09-18 US US09/957,698 patent/US6953591B2/en not_active Expired - Fee Related
- 2001-09-18 CA CA002422686A patent/CA2422686A1/en not_active Abandoned
- 2001-09-18 AU AU2001293553A patent/AU2001293553A1/en not_active Abandoned
- 2001-09-18 EP EP01973889A patent/EP1324750A1/en not_active Withdrawn
- 2001-09-18 JP JP2002528198A patent/JP2004508423A/en active Pending
- 2001-09-18 WO PCT/CA2001/001328 patent/WO2002024162A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20020086049A1 (en) | 2002-07-04 |
| WO2002024162A1 (en) | 2002-03-28 |
| EP1324750A1 (en) | 2003-07-09 |
| CA2319928A1 (en) | 2002-03-18 |
| US6953591B2 (en) | 2005-10-11 |
| JP2004508423A (en) | 2004-03-18 |
| CA2422686A1 (en) | 2002-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
| AU775126C (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| HUP0203367A3 (en) | Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes | |
| AU2001256184A1 (en) | 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases | |
| AU2001275177A1 (en) | Cardiac disease treatment and device | |
| AU2001253565A1 (en) | Cardiac disease treatment and device | |
| AU2001275176A1 (en) | Cardiac disease treatment and device | |
| AU2003243551A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
| AU2001281369A1 (en) | Cardiac disease treatment and device | |
| AU2002227300A1 (en) | Reducing cellular damage in the human body | |
| GB0109414D0 (en) | Well treatment fluids and methods for the use thereof | |
| HK1061212A1 (en) | Pyranoindazoles and their use for the treatment ofglaucoma | |
| AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
| AU4289100A (en) | Dihydropyrimidines and their use in the treatment of hepatitis | |
| HUP0400069A3 (en) | Pharmaceutical combinations and their use in preventing and treating the thrombosis | |
| AU1164601A (en) | Therapeutic use and formulation | |
| WO2003099841A9 (en) | Peptides and the use thereof in darkening the skin | |
| AU5240700A (en) | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis | |
| AU2837301A (en) | Use of polymeric material in the treatment of hard surfaces | |
| AU2002243363A1 (en) | Use of aziridino-compounds in the treatment of immune dysfunctions | |
| AU2003238242A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
| AU2001292797A1 (en) | Metal complexes for use in medical and therapeutic applications | |
| GB0011052D0 (en) | Medical device and use thereof | |
| AU2001261375A1 (en) | Human caspase-12 materials and methods | |
| AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |